Designing The Exit: IP Strategy For Venture-Backed Biotech

In venture-built biotech, value is not created at the point of exit, but is designed into the asset from the very beginning.

The earliest decisions made around a scientific discovery – how it is framed, developed, and protected – have a disproportionate impact on whether a company ultimately becomes fundable, partnerable, and acquirable. For early-stage investors, venture builders, and companies working on developing breakthrough cures and deep biotech, this dynamic is even more pronounced. Companies are not simply funded, they are constructed from the ground up, for their eventual exit.

Too often, intellectual property is often treated as sideshow in this process, a technical or legal necessity to be dealt with as and when seems necessary. However, IP is far more fundamental: ultimately, it is the asset you are selling, licencing, or being acquired for, and needs to be viewed as such.